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Abstract
Background To evaluate if conjunctival epithelial cells’ ex-
pression of HLA-DR and ICAM-1 could be helpful as early
topical markers of inflammation in Graves’ orbitopathy (GO).
Methods The ocular examination evaluated a clinical activity
score (CAS) by assessment of clinical features, (e.g., eyelid or
conjunctival inflammation, lid width, lid closure, proptosis,
ocular motility). Conjunctival epithelial cell specimens for
flow-cytometric evaluations of ICAM-I and HLADR expres-
sion were collected by impression cytology from ten eyes with
active GO (CAS≥4 and duration≤12 months), from 15 eyes
with Graves’ disease (GD) without active GO (CAS 0–2) and
from 15 normal specimens without any ocular disorders.
Results The percentage of HLA-DR+conjunctival epithelial
cells was significantly elevated in patients with active GO
comparing to GD without active GO and healthy controls,
10.7 % (8.5–17.7) and 7.78 % (3.92–10.1) (p<0.05) vs.
control 4.89 % (3.5–5.5) (p<0.005), respectively. The expres-
sion of ICAM−1+ conjunctival epithelial cells was greater
only in patients with GO vs. controls, 5.5 % (4.8–7.03) and
1.46 % (0.69–2.51) (p<0.005), respectively.
Conclusion The percentage of HLA-DR+ and ICAM-1+ con-
junctival epithelial cells in patients with the active GO may
serve as a topical inflammationmarker in Graves’ orbitopathy.
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Introduction
Development of flow cytometric analysis of cytologic speci-
mens provides a new, sensitive and objective tool for explor-
ing conjunctival pathology [1]. Conjunctival epithelium ex-
pression of HLA-DR (human leukocyte antigen-DR) and
ICAM-1 (intercellular adhesionmolecule-1) have been shown
to be correlated with some topical inflammatory processes like
allergic conjunctivitis, pterygium, or keratoconjunctivitis
sicca (KCS) in cystic fibrosis [2–6].
During inflammation, the expression of endothelial
and epithelial ICAM-1 increases [7]. ICAM-1 attracts
leukocytes to the conjunctival surface and holds them
there [8]. Conjunctival expression of HLA-DR is normal-
ly restricted to resident dendritic cells, but induction of
class II antigens in epithelial cells has consistently been
shown to be associated with conjunctival inflammatory
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reactions [5, 7, 8]. Graves’ orbitopathy (GO) is known to
be an autoimmune process leading to inflammation of
the orbital tissue [9]. In addition, almost all patients with
GO show signs of ocular surface damage [10]. Hence,
detection of HLA-DR and ICAM-1 molecules on the
conjunctiva may suggest activity of the immunopatho-
logical process underlying Graves' orbitopathy which
should be considered as an indication of intensive sys-
temic immunosuppression.
The objective of this study was to evaluate the ex-
pression of ICAM-1 and HLA-DR in conjunctival epi-
thelial cells by flow cytometry in patients with active
GO and Graves disease (GD) without active GO, in
order to estimate if the conjunctival expression of these
molecules could serve as topical markers of ongoing
inflammation in the active GO.
Materials and methods
Patients and controls
Conjunctival impression cytology was obtained from ten
eyes (ten patients) (eight females, two males) a mean
age of 35.9±9.9 years (range 26–46 years) with active
GO (CAS≥4), from 15 eyes (15 patients)(12 females,
three males) with a mean age of 36.5±11.5 years (range
25–48 years) with GD without signs of active GO,
recruited from the Department of Endocrinology,
Diabetology and Internal Diseases of Medical University
of Bialystok. Fifteen impression cytology specimens
were obtained from 15 eyes of ten healthy volunteers
(eight females, two males) a mean age of 34.5±12 years
(range 22.5–47 years) to serve as a control.
The study was carried out with approval from the Ethics
Committee of the Medical University of Bialystok, in accor-
dance with the guidelines of the Helsinki Declaration. All
patients and control persons gave their informed consent prior
to inclusion in this study.
Clinical examination
The ocular examination evaluated the best corrected
visual acuity (Snellen charts), colour vision (Ishihara
charts), intraocular pressure (applanation tonometry)
and exophthalmus. The GO clinical activity score in-
cluded measurements of lid aperture, marginal reflex
distance, the presence of eyelid retraction, eyelid or
conjunctival inflammation, biomicroscopic examination
of the anterior segment, indirect ophthalmoscopy, and
ocular motility.
Grouping of patients
Signs of GO in the eye were classified according to the
Clinical Activity Score (CAS) classification and NOSPECS
amended by EUGOGO [11]:
1) active GO – CAS equal to or greater than 4 and/or
NOSPECS equal to or greater than 5 (marked symptoms
of GO); Manifestation of GO≤12 months.
2) GD without signs of active GO – CAS less than 4 and
NOSPECS less than 5 (mild symptoms of GO) or no
signs of ophthalmopathy.
Exclusion criteria Patients with allergic conjunctivitis, dry
eye, blepharitis, uveitis, infective conjunctivitis or keratitis
were excluded from the study. Also, patients with a history
of ocular surgery within the last three months or patients with
any other ocular disease that might alter the markers to be
measured were excluded from the study. Patients receiving
topical corticosteroids or anti-inflammatory treatment within
the last month or patients who had radioiodine therapy or with
any immune system disease were also excluded.
Impression cytology of conjunctival epithelial cells and flow
cytometric assessment
After topical anaesthesia with 1–2 drops of 0.04 %
oxybuprocaine, two parts 13×6.5 mm in size (polyethersulfone
filter, 0.20-μmpores, Supor, Gelman Sciences, AnnArbor,MI)
were applied onto the superior and superiortemporal bulbar
conjunctiva without exerting any pressure. All membranes
were immediately dipped into tubes containing 1.5 ml of cold
phosphate-buffered saline (PBS) with fixative (0.05 % parafor-
maldehyde). Cells were extracted by gentle agitation for 20min
and centrifuged (1,800 rpm, 5 min). For each sample 2,000–
5,000 cells were analyzed and their fluorescence output was
displayed on a log scale. Monoclonal antibodies with fluoro-
chromes: CD54-FITC (mouse IgG1, clone 6.5B5) and antibod-
ies against class II antigen HLA-DR-FITC and EpCAM-
PerCP-Cy5.5 (mouse IgG1, clone EBA-1) antibodies were
purchased from DakoCytomation (Copenhagen, Denmark)
and Becton Dickinson (Mountain View, CA, USA),
respectively. A nonimmune mouse IgG1-FITC (clone
DAK-G01) was used as a negative isotypic control
(DakoCytomation). Direct immunostainings were performed
with monoclonal antibodies for 30 min at 4º C. A two param-
eter analysis was performed to determine the expression of
ICAM-1 and HLA-DR molecules on EpCAM positive cells
(conjunctival epithelial cells). The flow cytometric analysis
was performed with a Coulter Epics-XL flow cytometer
(Beckman Coulter Corporation, Miami, FL, USA). The re-
sults are expressed as a percentage of positive cells (Fig. 1).
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Statistical analysis
The patients'characteristic data and ocular assessments are
given as mean ± SD or median with range (in brackets). The
median and quartile values of the ICAM-1+ and HLADR+
conjunctival epithelial cells were presented. The statistical
significance of the evaluated CEC subsets’ expression was
measured by the UMann–Whitney test. A p value of less than
0.05 was considered statistically significant. All data were
performed using Statistica 9.0 (StatSoft ®, Tulsa, OK,
U.S.A.).
Results
Clinical features of the study groups
All results obtained for GO dependent alterations have been
summerized in Table 1.
The expression of HLA-DR and ICAM-1 on CECs
The percentage of HLA-DR+ conjunctival epithelial cells was
significantly elevated in patients with active GO comparing to
GD without active GO and versus healthy controls (p<0.005
and p<0.,05 respectively) (Table 2, Fig. 2). Moreover the
median percentage of HLA-DR+ CEC in active GO (10.7 %
(8.5–17.7) was significantly greater than in patients with GD
without active GO (7.78 % (3.92–10.1) (p<0.05)). The medi-
an percentage of HLA-DR+epithelial cells in active GO was
two-folds higher than in healthy controls (10.7 % (8.5–17.7)
vs. 4.89 % (3.5–5.5)) (Table 2, Fig. 2).
The statistical analysis of ICAM-1+ conjunctival epithelial
cells revealed the elevated percentage of these cells in patients
with active GO vs. controls (5.5 % (4.8–7.03) and 1.46 %
(0.69–2.51), respectively)(p<0.005) (Table 2, Fig. 2). In pa-
tients with GD without active GO the expression of ICAM-1+
CECs was not increased comparing to control (2.42 % (0.94–
7.05) (Table 2).
Discussion
It was shown that incomplete blink, increased proptosis and
greater palpebral fissure width in GO accelerates tear evapo-
ration, which increases the fluid’s osmolarity and results in
ocular surface damage [10]. Recently, it has been found that
inflammation plays a key role in ocular surface damage of GO
[12–15]. The increased concentrations of tears’ inflammatory
Fig. 1 Flow cytometric scatter-
plots: first row of gates
demonstrates a specimen from
active GO patient, second row
shows a healthy control. 1A)
displays the CECs gating, 2A)
HLADR+ CECs’ cells counting,
3A) ICAM-1+ CECs’ counting
Table 1 Comparison of clinical features of active GO and GD patients
without active GO. Date are presented asmean ± SD, ormedian value and
max and min (in the brackets). F: female, M: male
Active GO GD without
active GO
p value
Number of specimens 10 eyes 15 eyes
Age 35.9±9.9 36.5±11.5 0.534
Sex 8 F/2 M 12 F/3 M
Time of GO (months) 5 (2–9) 8 (0–18)
Clinical activity score (CAS) 6 (4–8) 1 (0–2)
NOSPECS (Disease severity
classification)
6 (5–7) 2 (0–4)
Proptosis (mm) 22 (17–26) 18 (14–22) 0.08
Palpebral fissure width (mm) 12.5 (9–14) 11 (9–13) 0.20
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cytokines (IL-1β, IL- 6) and chemokine IL-8 in patients with
active vs. inactive TAO (thyroid associated ophthalmopathy)
supports this thesis [16]. Gupta suggested that TAO was a
potential (occult) cause of inflammatory ocular surface disease
with dry eye symptoms [12].
In our previous study, serum L-selectin and ICAM-1 were
found to be elevated in patients with active GO, suggesting
enhanced T cell recruitment [17]. In accordance with that, we
have shown an increased percentage of L-selectin+and
ICAM-1+ peripheral blood CD4+/CD8+ T cells in active
GO [18]. Since the orbital tissues are infiltrated with inflam-
matory and immune cells in GO [10], the ICAM-1 and the
HLA-DR expression on the ocular surface may serve as
markers of a inflammatory status in GO. ICAM-1 plays a
central role not only in T lymphocyte activation but also T
cell trafficking at the inflammatory sites, which may result in
amplification of the cellular immune process in active GO
(Bahn 2003). The presence of HLA-DR renders conjunctival
epithelial cells capable of presenting antigens, as investigated
by impression cytology, which could be an indirect indicator
of the involvement of the Th1 subset [19]. Not only the
increased percentage of HLA-DR+ CECs in patients with
active GO vs. controls, but also vs. GD patients without
active GO may suggests the local activation in these
patients is due to different immunological pathways. It
has been shown that the Th1 profile predominates in the
early active phase of GO [20], which can be attributed
to the local HLA-DR engagement. In agreement with
that, our study showed a significantly higher percentage
of HLA-DR+CECs in patients with active GO than in
patients without active GO.
Kulig et al., found that the serum levels of ICAM-1 seem to
be a more sensitive marker than MRI in the assessment of the
activity of GO [21]. Our study is one of the few that show the
topical activation markers may be useful for diagnosing active
GO. Further studies should be designed to elucidate the role of
conjunctival epithelial cells’ immunophenotyping in
Table 2 The median and quartile values of the percentage of HLADR+
and ICAM-1+ conjunctival epithelial cells in the studied groups
Parameter Active GO GD without
active GO
Ctrl.
HLA-DR % 10.7** (8.5–17.7) 7.78* (3.92–10.1) 4.89 (3.5–5.5)
ICAM-1 % 5.5** (4.8–7.03) 2.42 (0.94–7.05) 1.46 (0.69–2.51)
**p<0.005 active GO vs. controls
*p<0.05 active GO vs. GD without active GO for HLA-DR+ CECs
Fig. 2 The median and the interquartile range of (a) HLA-DR+, and (b)
ICAM-1+ conjunctival epithelial cells’ percentage in patient with active
GO, GD without active GO and controls (whiskers display the
interquartile range). (c) scatter plots of HLA-DR+CEC, and (d) scatter
plots of ICAM-1+ CEC in patients with active GO, GD without active
GO and controls (bold line displays median value)
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monitoring the effects of systemic immunomodulatory treat-
ment in active GO [17].
In conclusion, our results might be a good hint that the
HLA-DR+CECs and ICAM-1+ CECs immunophenotyping
could be a topical inflammation marker in active GO.
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